drugset / Trial / NCT03933787
Neuropeptide Y and Sympathovagal Balance
Phase 0
Completed
7 enrolled
Eric Grouzmann
Nicolas Bourdillon · collabPhilippe Eugster · collabgrégoire millet · collabgrégoire wuerzner · collab
RandomizedCrossoverQuadruple-blindBasic science
Summary
Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and Y2 receptors. This double-blind placebo-controlled crossover study investigated the sympathovagal balance during three exercises on a cycloergometer in healthy volunteers treated with saxagliptin (DPP4 inhibitor).
Timeline
- Start
- 2018-06-05
- Primary completion
- 2018-07-18
- Completion
- 2019-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | Oral |